• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Human Embryonic Stem Cell (hESC) Research - Global Strategic Business Report Product Image

Human Embryonic Stem Cell (hESC) Research - Global Strategic Business Report

  • ID: 2228035
  • July 2012
  • Region: Global
  • 299 Pages
  • Global Industry Analysts, Inc

This report analyzes the worldwide markets for Human Embryonic Stem Cell (hESC) Research in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. The report profiles 26 companies including many key and niche players such as Advanced Cell Technology, Inc., BD Biosciences, BioTime, Inc., Cell Cure Neurosciences Ltd., Cellartis AB, GE Healthcare, Millipore Corporation, Molecular Transfer, Inc., PerkinElmer, Inc., Pfizer, Inc., Research & Diagnostics Systems, Inc., Reliance Life Sciences Ltd., Stem Cell Network, Stemina Biomarker Discovery, Inc., UK Stem Cell Bank, and ViaCyte, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying

Note: Product cover images may vary from those shown

HUMAN EMBRYONIC STEM CELL (HESC) RESEARCH

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Embryonic Stem Cells I-3

II. Executive Summary

1. INDUSTRY OVERVIEW II-1
Stem Cell Therapy - Continues to Traverse from Concept to Reality II-1
Stem Cell Market on the Verge of Rapid Growth II-1
Stem Cells Bodes Tremendous Potential in the Area of Medicine II-2
Issues Hold Back Development of Stem Cell Therapies II-2
Advantages and Drawbacks of Various Stem Cells II-3
Korea Debuts the World's First Somatic Stem Cell-Based Therapy II-3
An Introduction to Embryonic Stem Cells II-3
Embryonic Stem Cells - Sources and Cell Culture II-4

2. MARKET DYNAMICS II-5
Clinical Development in Adult stem cells Moves Ahead, Lurches
in hESCs II-5
Major Historical Events in the Area of Embryonic Stem Cell
Research II-5
Long Wait Imperative for Stem Cell Therapies II-6
Comparison on Adult and Embryonic Stem Cells II-6
Ethical Issues and Technical Hurdles Bog Down hESC Research II-6
Teratomas - No Longer an Impediment to Stem Cell Therapy
Development II-7
Induced Pluripotent - A Potential Competitor to hESCs? II-8
Intricate Differences Exist between hESC and iPS Cells II-8

3. REGULATORY LANDSCAPE II-9
The Global Divide in hESC Research II-9
Human Embryonic Stem Cell Regulation in Select Countries
Worldwide II-9
The IP Scenario in the Embryonic Stem Cells Research II-10
Impact of WARF Patents on Further Research II-10
WARF Fails to Gain Patents in Europe II-10
Diversity in Patent Regimes Pose Tremendous Challenges II-11
International Divide on Patenting Dents hESC Research II-11

4. HESC APPLICATION AREAS II-12
Drug Testing II-12
Embryonic Stem Cells in Drug Toxicity Testing II-12
Therapies II-12
hESCs in Neurological Conditions II-12
hESC-Based Parkinsons Disease Therapy Inching towards Human
Trials II-13
hESC-Based Alzheimer's Disease Therapy Advances Ahead in
Research II-13
Embryonic Stem Cells in Multiple Sclerosis Treatment II-14
Sporadic Human Trials in Cardiovascular Regeneration
Indicate Potential II-14
Cardiac Progenitor Cells in Repairing Myocardial Infarction II-14
Stem Cell Research in Cardiovascular Repair Rife with Hurdles II-15
New Research Breakthrough Rekindle Hopes II-15
Other Recent Advances in ES Cell-Based Cardiovascular Therapy II-16
hESCs in Diabetes Treatment II-16
ViaCyte's hESC Implant for Diabetes II-16
New Technique Wards off Teratoma Concerns II-17
Issues Present New Challenges for Human Trials II-17
hESC Cancer Therapy Research Makes Rapid Advances II-17
ES Cell-Derived Hair Cells- A Potential Treatment for Hearing
Loss II-18
Cartilage from ESCs Bodes Joint Disease Therapy Development II-18
ES Cells Hold Potential in Infertility Treatment II-18
University of California Pushes Memory Loss Treatment to New
Level II-18
ES Cells Hold Potential to Defy Age-Related Muscular
Deterioration II-19
hESCs in Tissue Repair - Auguring its Potential in
Regenerative Medicine II-19
Organ Creation & Other Applications II-19
hESCs in Organ Creation - A New Breakthrough from Japanese
Scientists II-19
Rudimentary Eye Creation Fortifies the Potential of ES Cells II-20
Therapy for Blood Disorders Still in Infancy II-20
Creation of Synthetic Blood - An Interesting Application of
hESCs II-21
Platelet Generation - A New Application of hESCs II-21
ES Cells-Based Lung Therapy Can Oust the Need for
Transplantations II-21

5. COMPETITION II-22
Select Companies Involved in Research of hESC- Based Therapies II-22
Geron - The First to Obtain FDA Clearance for Human Clinical
Trials on hESCs II-22
GRNOPC1 - Geron's hESC-Based Therapy for Spinal Cord Injury II-22
Initial Results Positive from GRNOPC1 Study II-22
Patient Enrolment Troubles Marr Geron's Clinical Development
of GRNOPC1 II-23
Geron's hESC-Based Regenerative Medicine Pipeline II-23
Geron's Decision to Quit hESC-Based Therapy Development
Shocks the Research World II-23
Advanced Cell Technology Commences First hESC Clinical Trial
in Europe II-24

6. PRODUCT INTRODUCTIONS/LAUNCHES II-25
GE Healthcare Introduces Human Cardiomyocytes II-25
Geron and Corning Introduce Synthemax™ Surface II-25
Thermo Fisher Scientific Rolls-Out Thermo Scientific Nunclon
Vita Stem Cell Culture Surface II-26
Lifeline Cell Technology Introduces Xeno-Free Culture Reagents
and Human Cells II-26
BioTime to Introduce Eleven New Cell Line Products II-26
Invitrogen Introduces KNOCKOUT™ SR Xeno Free Media II-27
Millipore Introduces ESGRO Complete™ PLUS Medium II-27

7. RECENT INDUSTRY ACTIVITY II-28
BioTime to Market Progenitors of Muscle Stem Cells II-28
ISCO and University of California Scientists Collaborate for
Ophthalmology Program II-28
Geron Discontinues hESC Trial II-28
ILS Partners with Stemina for Advancing hESC-Based Toxicology
Testing Tools II-29
Roslin Cells Inks Agreement with Pfizer II-29
BioTime Obtains NIH Approval for its hES Cell Lines II-29
Roslin Cellab Selects CoolCell from BioCision II-29
BioTime to Take Over Glycosan BioSystems II-30
BioTime Takes Over Assets of Cell Targeting II-30
NeoStem Merges with Progenitor Cell Therapy II-30
UK Stem Cell Bank and UMASS Stem Cell Bank to Ink a MoU II-31
BioTime Takes Over ESI II-31
ACT Inks MoU with Roslin Cells II-31
BioTime Asia Inks Marketing Agreement with Shanghai Genext II-32
BioTime Establishes New Subsidiary II-32
UC Irvine Develops Early Stage Eight-Layer Retina from Human
Embryonic Stem Cells II-32
Geron Enters into Partnership with University Campus Suffolk II-33
BioTime Inks Agreement with California Institute for
Regenerative Medicine II-33
Molecular Transfer Takes Over GlobalStem II-33
Geron Secures FDA Approval for First Embryonic Stem-Cell Trial II-33
StemCells, Inc. Takes Over Stem Cell Sciences II-34
Embryome Sciences and Reproductive Genetics Institute Enter
into Marketing Agreement II-34
Millipore and Embryome Sciences Enter into Co-Marketing Agreement II-35
GE Healthcare Signs Agreement with Geron II-35
Wisconsin Alumni Research Foundation and Pfizer Ink Licensing
Agreement II-36
WARF, Invitrogen Ink Agreement II-36

8. FOCUS ON SELECT GLOBAL PLAYERS II-37
Advanced Cell Technology, Inc. (US) II-37
BD Biosciences (US) II-37
BioTime, Inc. (US) II-38
Cell Cure Neurosciences Ltd. (US) II-38
Cellartis AB (Sweden) II-38
GE Healthcare (UK) II-39
Millipore Corporation (US) II-39
Molecular Transfer, Inc. (US) II-39
PerkinElmer, Inc. (US) II-40
Pfizer, Inc. (US) II-40
Research & Diagnostics Systems, Inc. (US) II-41
Reliance Life Sciences Ltd. (India) II-41
Stem Cell Network (Canada) II-42
Stemina Biomarker Discovery, Inc. (US) II-42
UK Stem Cell Bank (UKNSCB) (UK) II-42
ViaCyte, Inc. (US) II-43

9. GLOBAL MARKET PERSPECTIVE II-44
Table 1: Global Recent Past, Current & Future Analysis for
Human Embryonic Stem Cell Research by Geographic Region - US,
Europe, and Rest of World Markets Independently Analyzed with
Annual Investment Figures in US$ Million for Years 2009
Through 2018 (includes corresponding Graph/Chart) II-44

Table 2: World 10-Year Perspective for Human Embryonic Stem
Cell Research by Geographic Region - Percentage Breakdown of
Annual Investments for US, Europe and Rest of World Markets
for Years 2009, 2012 & 2018 (includes corresponding
Graph/Chart) II-45

III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Current & Future Analysis III-1
Stem Cell Market Outlook III-1
New hESC Lines under the Purview of Federal Funding Draws
Accolades from Scientists III-1
A Glimpse of Policy Framework on hESC Research in the US III-2
An Overview of NIH Guidelines on Funding in Stem Cell Research III-2
State Level Funding Continues to Persist in hESC Research III-2
Opposition Continues in Certain States
Oklahoma Vetoes
hESC Research in the State III-3
Previous Anti-hESC Research Policy Puts the US at a
Disadvantage III-3
Federal Appeals Court Gives Epic Ruling in Favor of hESC
Research Funding III-4
Product Launches III-4
Strategic Corporate Developments III-6
Select Key Players III-14
B.Market Analytics III-20
Table 3: US Recent Past, Current & Future Analysis for
Human Embryonic Stem Cell Research Market Analyzed with
Annual Investment Figures in US$ Million for Years 2009
Through 2018 (includes corresponding Graph/Chart) III-20

2. EUROPE III-21
A.Market Analysis III-21
Current & Future Analysis III-21
Overview of Legislations on hESC in Europe III-21
hESC Research Legislation in Select EU Countries III-21
FP7 in Embryonic Stem Cell Research III-21
Uncertainty Hovers on hESC Patenting in Europe III-22
Patent Laws in EU Covering hESCs III-22
New European Ruling on Patents Casts a Cloud on Future of
hESC Research III-23
Scientists Contest Recommendation on Ban of hESC Patents in
Europe III-23
Fears of hESC Research Wipe Out from Europe Increases III-24
Uncertainty Peeves Industry Players III-24
All's Not Done Yet for hESC Research in the EU III-24
Product Launches III-24
Strategic Corporate Developments III-25
Select Key Players III-26
B.Market Analytics III-27
Table 4: European Recent Past, Current & Future Analysis
for Human Embryonic Stem Cell Research Market Analyzed with
Annual Investment Figures in US$ Million for Years 2009
Through 2018 (includes corresponding Graph/Chart) III-27

3. REST OF WORLD III-28
A.Market Analysis III-28
Current & Future Analysis III-28
South Korea Pacing towards Regaining Lost Glory in Stem Cell
Research III-28
Korea Upbeat on Stem Cell Therapy Market Potential III-28
Australia Persists with Former Laws on hESC III-28
Issues Stem from the First Brazilian Embryonic Stem Cell Line III-29
Strategic Corporate Development III-29
Select Key Players III-30
B.Market Analytics III-32
Table 5: Rest of World Recent Past, Current & Future
Analysis for Human Embryonic Stem Cell Research Market
Analyzed with Annual Investment Figures in US$ Million for
Years 2009 Through 2018 (includes corresponding
Graph/Chart) III-32

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 26 (including Divisions/Subsidiaries - 31)

The United States (24)
Canada (1)
Europe (4)
- The United Kingdom (1)
- Rest of Europe (3)
Asia-Pacific (Excluding Japan) (1)
Middle-East (1)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos